Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding .1 billion in 2011. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2011, R&D expenditure totaled more than 50 million, above 21% of Group sales. The Group has total worldwide staff of close to 4,500.
Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the Serv... (Source: SEC reports)
Competitor - 1/8
Which company is more competitive with Ipsen S.A. inc?